Chimeric Antigen Receptors
We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.
Advanced Cell Programming
Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.
T Cell Manufacturing
We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other advanced cell programing modules.
The company’s lead therapeutic candidate, obe-cel, is a potentially transformational treatment for adult Acute Lymphoblastic Leukemia. Obe-cel is an autologous CD19 CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a “fast-off” kinetic which mimics physiological T cell receptor interactions. Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile results in increased T cell persistence leading to high levels of durable remissions and remarkably low levels of cytokine release syndrome and other immunotoxicities. Obe-cel is currently being evaluated in the potentially pivotal FELIX study in adult ALL and in phase 1 studies for other B-NHL indications. Obe-cel phase 2 pivotal FELIX clinical trial met its primary endpoint at an interim analysis in 2022 with additional data expected in mid-2023.Find out more
Our Obe-cel Abstracts and Publications
Get the latest updates from Autolus on new research, company news and eventsView all news
Information for patients
Clinical trials are required to gain regulatory approval for new medicines to advance patient care.Learn more about our CAR T cell therapy clinical trials
Life at Autolus
Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.Careers at Autolus
Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.View investor information